147 related articles for article (PubMed ID: 8951966)
41. Felbamate increases [3H]glycine binding in rat brain and sections of human postmortem brain.
McCabe RT; Sofia RD; Layer RT; Leiner KA; Faull RL; Narang N; Wamsley JK
J Pharmacol Exp Ther; 1998 Aug; 286(2):991-9. PubMed ID: 9694960
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones.
Grasso S; De Sarro G; De Sarro A; Micale N; Zappalà M; Puja G; Baraldi M; De Micheli C
J Med Chem; 2000 Jul; 43(15):2851-9. PubMed ID: 10956193
[TBL] [Abstract][Full Text] [Related]
43. A neuropharmacological evaluation of felbamate as a novel anticonvulsant.
White HS; Wolf HH; Swinyard EA; Skeen GA; Sofia RD
Epilepsia; 1992; 33(3):564-72. PubMed ID: 1592038
[TBL] [Abstract][Full Text] [Related]
44. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice.
Taylor CP; Vartanian MG
Eur J Pharmacol; 1992 Mar; 213(1):151-3. PubMed ID: 1499653
[TBL] [Abstract][Full Text] [Related]
45. Reduction of dizocilpine and scopolamine-induced deficits in avoidance responding by SCH 54388, a metabolite of felbamate.
Smith RD; Grzelak ME; Coffin VL
Pharmacol Biochem Behav; 1997 Nov; 58(3):657-64. PubMed ID: 9329055
[TBL] [Abstract][Full Text] [Related]
46. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit.
Harty TP; Rogawski MA
Epilepsy Res; 2000 Mar; 39(1):47-55. PubMed ID: 10690753
[TBL] [Abstract][Full Text] [Related]
47. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
[TBL] [Abstract][Full Text] [Related]
48. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors.
Rho JM; Donevan SD; Rogawski MA
Ann Neurol; 1994 Feb; 35(2):229-34. PubMed ID: 8109904
[TBL] [Abstract][Full Text] [Related]
50. Amino acid derivatives with anticonvulsant activity.
Paruszewski R; Strupińska M; Stables JP; Swiader M; Czuczwar S; Kleinrok Z; Turski W
Chem Pharm Bull (Tokyo); 2001 May; 49(5):629-31. PubMed ID: 11383620
[TBL] [Abstract][Full Text] [Related]
51. Felbamate modulates the strychnine-insensitive glycine receptor.
White HS; Harmsworth WL; Sofia RD; Wolf HH
Epilepsy Res; 1995 Jan; 20(1):41-8. PubMed ID: 7713059
[TBL] [Abstract][Full Text] [Related]
52. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site.
Nichols AC; Yielding KL
Mol Chem Neuropathol; 1998; 35(1-3):1-12. PubMed ID: 10343967
[TBL] [Abstract][Full Text] [Related]
53. Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-(F)-quinoxaline.
Ikonomidou C; Turski L
Ann N Y Acad Sci; 1997 Oct; 825():394-402. PubMed ID: 9370004
[No Abstract] [Full Text] [Related]
54. Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene.
De Sarro G; Donato Di Paola E; Falconi U; Ferreri G; De Sarro A
Eur J Pharmacol; 1996 Dec; 317(2-3):239-45. PubMed ID: 8997606
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor.
Cai SX; Kher SM; Zhou ZL; Ilyin V; Espitia SA; Tran M; Hawkinson JE; Woodward RM; Weber E; Keana JF
J Med Chem; 1997 Feb; 40(5):730-8. PubMed ID: 9057859
[TBL] [Abstract][Full Text] [Related]
56. Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular Ca2+ concentration.
Taylor LA; McQuade RD; Tice MA
Eur J Pharmacol; 1995 Apr; 289(2):229-33. PubMed ID: 7621896
[TBL] [Abstract][Full Text] [Related]
57. Felbamate and meprobamate: a comparison of their anticonvulsant properties.
Frey HH; Bartels I
Epilepsy Res; 1997 Jun; 27(3):151-64. PubMed ID: 9237049
[TBL] [Abstract][Full Text] [Related]
58. Felbamate but not phenytoin or gabapentin reduces glutamate release by blocking presynaptic NMDA receptors in the entorhinal cortex.
Yang J; Wetterstrand C; Jones RS
Epilepsy Res; 2007 Dec; 77(2-3):157-64. PubMed ID: 17980555
[TBL] [Abstract][Full Text] [Related]
59. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex.
Tricklebank MD; Bristow LJ; Hutson PH; Leeson PD; Rowley M; Saywell K; Singh L; Tattersall FD; Thorn L; Williams BJ
Br J Pharmacol; 1994 Nov; 113(3):729-36. PubMed ID: 7858861
[TBL] [Abstract][Full Text] [Related]
60. Effects of antiepileptic drugs, calcium channel blockers and other compounds on seizures induced by activation of voltage-dependent L calcium channel in DBA/2 mice.
De Sarro G; Ascioti C; di Paola ED; Vidal MJ; De Sarro A
Gen Pharmacol; 1992 Nov; 23(6):1205-16. PubMed ID: 1283140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
